Circular RNA hsa_circ_0044234 as distinct molecular signature of triple negative breast cancer: a potential regulator of GATA3
- PMID: 34126989
- PMCID: PMC8201848
- DOI: 10.1186/s12935-021-02015-6
Circular RNA hsa_circ_0044234 as distinct molecular signature of triple negative breast cancer: a potential regulator of GATA3
Abstract
Background: Circular RNAs (circRNAs) have been implicated in the initiation and development of breast cancer as functional non-coding RNAs (ncRNA). The roles of circRNAs as the competing endogenous RNAs (ceRNAs) to sponge microRNAs (miRNAs) have also been indicated. However, the functions of circRNAs in breast cancer have not been totally elucidated. This study aimed to explore the clinical implications and possible roles of circ_0044234 in carcinogenesis of the most problematic BC subtype, triple negative breast cancer (TNBC), which are in desperate need of biomarkers and targeted therapies.
Methods: The importance of circ_0044234 as one of the most dysregulated circRNAs in TNBC was discovered through microarray expression profile analysis. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to confirm the downregulation of circ_0044234 in triple negative tumors and cell lines versus non-triple negative ones. The bioinformatics prediction revealed that circ_0044234 could act as an upstream sponge in the miR-135b/GATA3 axis, two of the most dysregulated transcripts in TNBC.
Results: Our experimental investigation of circ_0044234 expressions in various BC subtypes as well as cell lines reveals that TNBC expresses circ_0044234 at a substantially lower level than non-TNBC. The ROC curve analysis indicates that it could be applied as a discriminative biomarker to identify TNBC from other BC subtypes. Moreover, circ_0044234 expression could be an independent prognostic biomarker in BC. Interestingly, a substantial inverse expression correlation was detected between circ_0044234 and miR-135b-5p as well as between miR-135b-5p and GATA3 in breast tumors.
Conclusions: The possible clinical usefulness of circ_0044234 as a promising distinct biomarker and upcoming therapeutic target for TNBC have been indicated in this research. Our comprehensive approach revealed the potential circ_0044234/miR135b-5p/GATA3 ceRNA axis in TNBC.
Keywords: Bioinformatics; GATA3; Triple negative breast cancer; ceRNA; circ_0044234; miR135b-5p.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures






Similar articles
-
Evaluation of Circ_0000977-Mediated Regulatory Network in Breast Cancer: A Potential Discriminative Biomarker for Triple-Negative Tumors.Biochem Genet. 2023 Aug;61(4):1487-1508. doi: 10.1007/s10528-023-10331-x. Epub 2023 Jan 16. Biochem Genet. 2023. PMID: 36645554
-
CircRNA hsa_circ_0006220 acts as a tumor suppressor gene by regulating miR-197-5p/CDH19 in triple-negative breast cancer.Ann Transl Med. 2021 Aug;9(15):1236. doi: 10.21037/atm-21-2934. Ann Transl Med. 2021. PMID: 34532373 Free PMC article.
-
Circular RNA-associated ceRNA network involved in HIF-1 signalling in triple-negative breast cancer: circ_0047303 as a potential key regulator.J Cell Mol Med. 2021 Dec;25(24):11322-11332. doi: 10.1111/jcmm.17066. Epub 2021 Nov 17. J Cell Mol Med. 2021. PMID: 34791795 Free PMC article.
-
Circular RNA: A potential diagnostic, prognostic, and therapeutic biomarker for human triple-negative breast cancer.Mol Ther Nucleic Acids. 2021 Jul 2;26:63-80. doi: 10.1016/j.omtn.2021.06.017. eCollection 2021 Dec 3. Mol Ther Nucleic Acids. 2021. PMID: 34513294 Free PMC article. Review.
-
The therapeutic potential of circular RNA in triple-negative breast cancer.Cancer Drug Resist. 2024 Apr 23;7:13. doi: 10.20517/cdr.2023.141. eCollection 2024. Cancer Drug Resist. 2024. PMID: 38835343 Free PMC article. Review.
Cited by
-
Genomic Alterations Affecting Competitive Endogenous RNAs (ceRNAs) and Regulatory Networks (ceRNETs) with Clinical Implications in Triple-Negative Breast Cancer (TNBC).Int J Mol Sci. 2024 Feb 23;25(5):2624. doi: 10.3390/ijms25052624. Int J Mol Sci. 2024. PMID: 38473871 Free PMC article. Review.
-
Circular RNAs as Biomarkers in Breast Cancer Diagnosis, Prognosis, Molecular Types, Metastasis and Drug Resistance.Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251328500. doi: 10.1177/15330338251328500. Epub 2025 Mar 13. Technol Cancer Res Treat. 2025. PMID: 40080898 Free PMC article. Review.
-
Circular RNAs as novel biomarkers in triple-negative breast cancer: a systematic review.Mol Biol Rep. 2022 Oct;49(10):9825-9840. doi: 10.1007/s11033-022-07502-1. Epub 2022 May 10. Mol Biol Rep. 2022. PMID: 35534586
-
Circular RNAs as Potential Biomarkers in Breast Cancer.Biomedicines. 2022 Mar 21;10(3):725. doi: 10.3390/biomedicines10030725. Biomedicines. 2022. PMID: 35327527 Free PMC article. Review.
-
miR-135b: A key role in cancer biology and therapeutic targets.Noncoding RNA Res. 2025 Feb 20;12:67-80. doi: 10.1016/j.ncrna.2025.02.005. eCollection 2025 Jun. Noncoding RNA Res. 2025. PMID: 40124960 Free PMC article. Review.
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):209–249. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources